Clinical Trials Sponsored by RespireRx

Total 40 results

RespireRx

Completed

Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.

Mild Cognitive Impairment

United States
RespireRx

Completed

CX717 in the Treatment of Adult ADHD

Attention Deficit Hyperactivity Disorder
RespireRx
Duke University

Unknown

Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia

Opiate Induced Respiratory Depression

United States
RespireRx
FRAXA Research Foundation

Completed

Effects of CX516 on Functioning in Fragile X Syndrome and Autism

Fragile X Syndrome | Autism

United States
Respivert Ltd

Completed

Safety, Tolerability and Pharmacokinetics (PK) of RV1162 in Healthy Subjects and COPD Patients

Healthy Volunteers | Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
Respivert Ltd

Completed

A Study to Investigate the Safety and Tolerability of a New Inhaled Formulation of RV568 in Healthy Volunteers

Healthy Volunteers | COPD

United Kingdom
Respivert Ltd

Completed

A Study to Investigate How Safe and Well Tolerated RV568 is in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United Kingdom
Respivert Ltd

Completed

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of RV1729 for 28 Days in Patients With COPD

Chronic Obstructive Pulmonary Disease

United Kingdom
Respivert Ltd

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729 for up to 28 Days

Asthma | Healthy Volunteers

United Kingdom
Respivert Ltd

Completed

RV568 - Viral Challenge With RSV

Respiratory Syncytial Virus Infections

United Kingdom
Respivert Ltd

Completed

Vienna Challenge Chamber Study Using RV658 in Subjects With Allergic Rhinitis

Seasonal Allergic Rhinitis

Austria
Respivert Ltd

Terminated

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of RV6153

Asthma | Healthy Volunteers

United Kingdom
Respivert Ltd

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729

Asthma | Healthy Volunteers

United Kingdom
Respivert Ltd

Completed

Sample Collection in Smoking Asthma

Asthma

United Kingdom
North Suffolk Mental Health Association
RespireRx

Completed

Trial of Ampakine Added to Clozapine, Olanzapine or Risperidone in Patients With Schizophrenia (CX516)

Schizophrenia

United States
Respirix, Inc.

Not yet recruiting

Correlation of Hemodynamics Via Pulmonary Artery Catherization and the Cardiospire

Hemodynamic Instability

United States
Respiree Pte Ltd

Completed

Respiratory Rate Validation Study - RS001.2 Respiree Cardio-Respiratory Monitor

A Minimum of 30 Adults, Ages 18 Years and Older

United States
Respiree Pte Ltd

Completed

Accuracy of Pulse Oximeters With Profound Hypoxia

Healthy Volunteers

United States
Respirent Pharmaceuticals Co Ltd.

Completed

A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma

Asthma

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Asthma | Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

Pooled Analysis FP_SX_250_50

Asthma

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pilot Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Respivert Ltd
Babraham Institute Enterprise Limited

Completed

Biomarker Assay Validation in Healthy Smokers and COPD Smokers and Ex-smokers

Asthma | COPD

United Kingdom
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Recruiting

Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Recruiting

A Bioequivalence Study Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions

Asthma | Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

A Bioequivalence Study Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 250 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions

Asthma | Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade (BREATH-PK250-CC)

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers (BREATH-PK500)

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Recruiting

Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma (AERO-PD)

Asthma

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100mcg/Blister Oral Inhalation Powder/GSK in Patients With Asthma (ANASSA-PD)

Asthma

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Asthma | Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
International Centre for Diarrhoeal Disease Research...
University of Edinburgh; NIHR Global Health Research Unit on Respiratory Health... and other collaborators

Completed

Feasibility and Acceptability Followed by Effectiveness of bCPAP for Treatment of Bangladeshi Children With Severe Pneumonia (Child-bCPAP)

Feasibility

Bangladesh

3

Subscribe